Specifically, PRDX6 demonstrates tissue-specific expression patterns, with downregulation observed in renal cell carcinoma [142]; while a substantial body of pre-clinical and clinical studies suggests PRDX6 upregulation in melanoma [98] and various solid tumors, including brain tumors [1,143], lung cancer [142,144,145,146,147,148,149], cervical carcinoma [142,150], endometrial cancer [142,151], ovarian cancer [142], skin malignancies [152], head and neck squamous cell carcinoma [153], and bladder cancer [142,154,155]. Here, PRDX6 is linked to lung cancer.